<DOC>
	<DOC>NCT00759408</DOC>
	<brief_summary>The purpose of the study is is to determine the effect, on the lung circulation, of BQ-123, an investigational compound which is not approved by the FDA.</brief_summary>
	<brief_title>The Role of Endothelin in Pulmonary Hypertension</brief_title>
	<detailed_description>Endothelin levels are increased in patients with pulmonary hypertension. We wish to compare the effect of an endothelin antagonist on pulmonary hypertension due to a variety of causes.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<mesh_term>cyclo(Trp-Asp-Pro-Val-Leu)</mesh_term>
	<criteria>known diagnosis of pulmonary hypertension hypertension due to other reasons (not pulmonary)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>primary pulmonary hypertension</keyword>
	<keyword>secondary pulmonary hypertension due to left heart failure</keyword>
	<keyword>secondary pulmonary hypertension due to other causes</keyword>
	<keyword>patients without pulmonary disease or pulmonary hypertension</keyword>
</DOC>